Uncategorized
FDA accepts NDA resubmission for Dextenza
The FDA has accepted a new drug application resubmission for Dextenza to treat ocular pain after ophthalmic surgery, according to a press release from Ocular Therapeutix.Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use is designed to deliver a tapered dexamethasone dose to the ocular surface for up to 30 days after ocular surgery.